Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Kaposi 3Myeloproliferative Disorders 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Acquired Immunodeficiency Syndrome 2Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Epstein-Barr Virus Infections 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

AZD 6244 4pirfenidone 2trametinib 1tipifarnib 1pomalidomide 1omipalisib 1cediranib 1abemaciclib 1Waiting Lists 1Vincristine 1Surveys and Questionnaires 1Specimen Handling 1Sorafenib 1Pharmacokinetics 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Carboplatin 1Biopsy 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neurofibromatosis 1 × pomalidomide × Clear all
NCT02415153 2022-04-25

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
CNS

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡